Lv1
40 积分 2024-11-05 加入
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
13天前
已完结
ST segment and T wave abnormalities: A narrative review
26天前
已完结
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
2个月前
已完结
Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis
4个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
4个月前
已完结
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
4个月前
已完结
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
4个月前
已完结
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
5个月前
已完结
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
5个月前
已完结
皖公网安备34019202002308
